Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tranilast directly targets NLRP 3 to treat inflammasome‐driven diseases
Yi Huang, Hua Jiang, Yun Chen, et al.
EMBO Molecular Medicine (2018) Vol. 10, Iss. 4
Open Access | Times Cited: 425

Showing 1-25 of 425 citing articles:

The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Karen V. Swanson, Meng Deng, Jenny P.‐Y. Ting
Nature reviews. Immunology (2019) Vol. 19, Iss. 8, pp. 477-489
Open Access | Times Cited: 3550
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
Tao Gong, Lei Liu, Wei Jiang, et al.
Nature reviews. Immunology (2019) Vol. 20, Iss. 2, pp. 95-112
Closed Access | Times Cited: 1295
Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors
Yang Yang, Huanan Wang, Mohammed Kouadir, et al.
Cell Death and Disease (2019) Vol. 10, Iss. 2
Open Access | Times Cited: 1063
Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
Hongbin He, Hua Jiang, Yun Chen, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 614
Pharmacological Inhibitors of the NLRP3 Inflammasome
Ayesha Zahid, Bofeng Li, Arnaud John Kombe Kombe, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 563
An update on the regulatory mechanisms of NLRP3 inflammasome activation
Seungwha Paik, Jin Kyung Kim, Prashanta Silwal, et al.
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 5, pp. 1141-1160
Open Access | Times Cited: 533
NLRP3 and pyroptosis blockers for treating inflammatory diseases
Rebecca C. Coll, Kate Schroder, Pablo Pelegrı́n
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 8, pp. 653-668
Open Access | Times Cited: 441
The NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Li Wang, Arthur V. Hauenstein
Molecular Aspects of Medicine (2020) Vol. 76, pp. 100889-100889
Closed Access | Times Cited: 326
NLRP3 Inflammasome and Inflammatory Diseases
Zheng Wang, Simei Zhang, Ying Xiao, et al.
Oxidative Medicine and Cellular Longevity (2020) Vol. 2020, pp. 1-11
Open Access | Times Cited: 279
The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases
Hallie Blevins, Yiming Xu, Savannah Biby, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 270
The role of inflammasomes in kidney disease
Takanori Komada, Daniel A. Muruve
Nature Reviews Nephrology (2019) Vol. 15, Iss. 8, pp. 501-520
Closed Access | Times Cited: 253
Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19
Jeremy Kean Yi Yap, Miyu Moriyama, Akiko Iwasaki
The Journal of Immunology (2020) Vol. 205, Iss. 2, pp. 307-312
Open Access | Times Cited: 249
Severe COVID-19: NLRP3 Inflammasome Dysregulated
Daan F. van den Berg, Anje A. te Velde
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 209
Gallic Acid Alleviates Gouty Arthritis by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis Through Enhancing Nrf2 Signaling
Yuqing Lin, Tianyu Luo, Anli Weng, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 199
NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword
Shaima’a Hamarsheh, Robert Zeiser
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 186
The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer's Disease
Kendra L. Hanslik, Tyler K. Ulland
Frontiers in Neurology (2020) Vol. 11
Open Access | Times Cited: 177
Therapeutic modulation of inflammasome pathways
Dhruv Chauhan, Lieselotte Vande Walle, Mohamed Lamkanfi
Immunological Reviews (2020) Vol. 297, Iss. 1, pp. 123-138
Open Access | Times Cited: 173
Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19
Adnan Muhammad Shah
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 169
Inflammasomes contributing to inflammation in arthritis
Lotte Spel, Fabio Martinon
Immunological Reviews (2020) Vol. 294, Iss. 1, pp. 48-62
Open Access | Times Cited: 152
P2X7 receptor and the NLRP3 inflammasome: Partners in crime
Pablo Pelegrı́n
Biochemical Pharmacology (2020) Vol. 187, pp. 114385-114385
Closed Access | Times Cited: 150
The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets
Tao Liang, Yang Zhang, Suyuan Wu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 129
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
Lieselotte Vande Walle, Mohamed Lamkanfi
Nature Reviews Drug Discovery (2023) Vol. 23, Iss. 1, pp. 43-66
Closed Access | Times Cited: 120
Impact of intracellular innate immune receptors on immunometabolism
Wei-Chun Chou, Elena Rampanelli, Xin Li, et al.
Cellular and Molecular Immunology (2021) Vol. 19, Iss. 3, pp. 337-351
Open Access | Times Cited: 113
RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor
Yun Chen, Hongbin He, Bolong Lin, et al.
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 6, pp. 1425-1436
Open Access | Times Cited: 107
Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target
Jiahao Chen, Qinhui Liu, Jinhan He, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 99
Page 1 - Next Page

Scroll to top